Ativa - Diagnostic Workstation for Covid-19 - Health Care - Medical Equipment
ATIVA’s rapid low-cost COVID-19 test may provide earlier detection and a safer community. The greatest challenge we face is the spread of infection before symptoms appear. We all want to protect our loved ones, so how do we know if we are carrying the virus? Physical symptoms (fever, cough) appear too late to stop the spread. The nasal swab PCR tests suffer from sampling errors, slow time to results, and are expensive. Early detection of infected people is the key to protecting our most vulnerable people in aged-care centers, cancer wards, our valued frontline workers (EMTs, nurses) and our essential workers in critical infrastructure or food processing jobs.
Most popular related searches
Using just a drop of blood, Ativa’s test may detect the body’s earliest immune response to infection, well before symptoms appear or antibodies emerge. There are very subtle but detectable changes in the white blood cells morphology and ratios within hours of infection. This is the innate immune response, and no other test is measuring this today. Ativa’s test is completed within 5-minutes and at the point-of-care.
Ativa’s low-cost COVID-19 triage test will help clinicians understand the immune system status of individual patients, enabling a risk-prediction to guide treatment decisions.
Using advanced A.I. algorithms, Ativa detects the early innate immune cell changes in blood (see image below). These include NK-cells, phagocytes, activated lymphocytes, T-cells, white cell ratios, nuclear-cytoplasm ratios and shifts in absolute cell counts. In viral infections, blood cell changes occur days before physical symptoms appear. Emerging evidence on blood changes during COVID-19 disease progression supports Ativa’s approach for detection, monitoring, staging and prognosis on disease severity. Ativa can even track the immune system recovery from mild to severe COVID cases and the body’s response to vaccines that trigger the immune cells.When will it be available?
Ativa is rapidly developing and validating this new test, with clinical studies underway. After FDA-approval, this test will be made available as quickly and widely as possible.